Role of HTLV-1 in the maintenance of malignant phenotype of ATL cells

Research Project

Project/Area Number	16K14623
Research Category	Grant-in-Aid for Challenging Exploratory Research
Allocation Type	Multi-year Fund
Research Field	Tumor biology
Research Institution	National Hospital Organization Nagoya Medical Center
Principal Investigator	Komano Atsushi 独立行政法人国立病院機構(名古屋医療センター臨床研究センター), その他部局等, 臨床検査科長 (60356251)
Research Collaborator	TAKEDA Satoshi 国立感染症研究所, 研究員 TANAKA Atsushi 大阪大学, 微生物学研究所, 助教 HOSHINO Tyuji 千葉大学, 薬学部, 准教授 OKADA Seiji 熊本大学, エイズ学センター, 教授
Project Period (FY)	2016-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000) Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords	HTLV-1 / ATL / provirus / genome editing / Protein transduction / LENA / ゲノム編集 / ZFN / CRISPR/Cas9 / LTR / malignant phenotype / genome loss / Cancer biology / パッセンジャー説
Outline of Final Research Achievements	HTLV-1 is a causative agent of adult T-cell leukemia (ATL) in humans. The role of HTLV-1 in the maintenance of malignant phenotype of ATL cells has remained clarified. We employed evolving genome editing technologies to remove the proviral genome of HTLV-1 from ATL cells to address this issue. We were able to detect a PCR signal, suggesting the proviral removal was successful. We have been trying to reproduce this finding and will analyze the biological properties of provirus-deleted ATL cells.